Loading clinical trials...
Loading clinical trials...
A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC)
Conditions
Interventions
Pembrolizumab
IMGN853
Locations
3
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Massachusetts
Worcester, Massachusetts, United States
Northwell Cancer Institute
Lake Success, New York, United States
Start Date
January 2, 2020
Primary Completion Date
June 4, 2024
Completion Date
May 1, 2027
Last Updated
May 15, 2025
NCT05489211
NCT04657068
NCT04585750
NCT07029399
NCT06975293
NCT07166094
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions